Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has released a corporate and operational update highlighting continued progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts. The company reported positive six-month results from its First-in-Human (FIH) study, supporting advancement to Group Two clinical surgeries.
The six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes, with successful implantation procedures and favorable post-operative results. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered legally blind who is now qualified to drive.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, incorporating significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance. The redesigned lens features a simplified one-piece design with no internal materials such as air, water or oil. Manufacturing of the redesigned lens has commenced with the company's German manufacturing partner, Amiplant GmbH.
All regulatory requirements necessary to proceed to Group Two surgeries have been successfully completed. Group Two surgeries remain on track for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the company's updated lens delivery system.
The company has launched a financing initiative to support completion of the FIH study and accelerate commercialization activities. Proceeds are expected to fund Group Two surgeries, finalize manufacturing and quality verification, complete sterilization and packaging, advance regulatory programs, and continue strategic partnership initiatives.
Strategic commercialization discussions continue with four of the world's seven largest ophthalmic companies. Management has met with representatives from these organizations to introduce the Ocumetics technology platform, and several have expressed interest in reviewing additional clinical data following Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026.
With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, and regulatory milestones achieved, management believes the company is well positioned to execute the next phase of its clinical development strategy and build long-term shareholder value.
